Alnylam Pharma (ALNY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Maury Raycroft from Jefferies maintained a Buy rating on the stock and has a $328.00 price target.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Maury Raycroft has given his Buy rating due to a combination of factors including Alnylam Pharma’s strong performance and strategic positioning in the market. The company has shown promising progress with the launch of Amvuttra CM, achieving rapid formulary inclusion and broad patient uptake, which indicates a strong commercial setup capable of capitalizing on the growing market for cardiomyopathy treatments.
Furthermore, Alnylam’s management has reiterated their revenue guidance and non-GAAP profitability targets for 2025, which reflects confidence in their financial outlook. The company’s limited exposure to potential tariff impacts and their strategic manufacturing and intellectual property positioning in the U.S. further bolster their market stability. Additionally, Alnylam’s competitive edge is highlighted by their ability to capture a significant share of new patients compared to competitors, alongside favorable pricing strategies and access initiatives that enhance patient affordability.
In another report released today, Chardan Capital also maintained a Buy rating on the stock with a $325.00 price target.
ALNY’s price has also changed slightly for the past six months – from $273.910 to $255.130, which is a -6.86% drop .